Leverage our comprehensive, tailored PGx solutions for drug R&D

Drug Research Laboratory

Leverage our comprehensive, tailored PGx solutions for drug R&D

Improve your R&D

Pharmacogenetics testing is an increasingly important tool for clinical trial enrollment, interpretation of clinical data and retrospective studies. Adverse drug reactions (ADR) caused by genetic variants can halt a trial, mandate a black-box warning label and result in an approved drug being withdrawn from the market. In some cases, drugs that fail to meet clinical efficacy endpoints for broader use, are nonetheless found to be effective for a subset of the population.

To help mitigate these costly risks of failed trials, we offer both comprehensive and tailored genotyping and next-generation sequencing (NGS) services for clinical trials and research studies. RPRD is a recognized leader in precision medicine research and clinical testing, bringing deep expertise and an unparalleled testing platform to organizations conducting clinical trials.

Customized, end-to-end PGx solutions

Since every drug development project is unique, we offer customized end-to-end solutions to meet each client’s specific needs. We provide precision medicine consulting services at each stage of a project to help guide our partners during the development process. Our consulting includes but is not limited to:

We partner closely with pharmaceutical companies and contract research organizations (CROs) to develop customized precision medicine solutions using NGS and genotyping (PharmacoScan or customized panels). Our focus is on high-quality data analysis and clinical interpretation to develop better, personalized therapies for tomorrow.

State-of-the-art PGx technologies

We offer comprehensive genomic profiling of clinical trial samples in our CLIA-certified laboratory utilizing our comprehensive genomic profiling tests based on NGS and the PharmacoScan platform.

Read more about our expertise in NGS.


PharmacoScanTM is an ideal genotyping platform for translational researchers in pharma and research organizations looking to understand how genetic variations affect drug absorption, distribution, metabolism, and excretion (ADME).

We can precisely and reproducibly analyze 4,627 biomarkers within nearly 1,200 genes.

The solution includes detecting copy number variation (CNV) and interrogating predictive markers in complex genes (e.g. CYP2D6).

Unlike other platforms that analyze only the common markers, our comprehensive testing approach presents a more complete view of genotype information that potentially lead to more accurate PGx risk evaluation.

PharmacoScan Genotyping Platform

PharmacoScan™ Assay Kit: www.thermofisher.com/order/catalog/product/903026

Leverage our End-to-End Solutions Today

To request a quote or to learn more about our capabilities.